Motesanib

• CAT Number: I003594
• CAS Number: 453562-69-1
• Molecular Formula: C₂₂H₂₃N₅O
• Molecular Weight: 373.45
• Purity: ≥95%
• Target: c-Kit
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• IC50: 2 nM/3 nM/6 nM/8 nM(VEGFR1/2/3/c-Kit) [1]
• IUPAC Name: N-(3,3-dimethyl-1,2-dihydroindol-6-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide
• InChI: InChI=1S/C22H23N5O/c1-22(2)14-26-19-12-16(5-6-18(19)22)27-21(28)17-4-3-9-24-20(17)25-13-15-7-10-23-11-8-15/h3-12,26H,13-14H2,1-2H3,(H,24,25)(H,27,28)
• InChIKey: RAHBGWKEPAQNFF-UHFFFAOYSA-N
• SMILES: CC1(CNC2=C1C=CC(=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4)C

Motesanib (Cat.No:I003594) is a small molecule tyrosine kinase inhibitor that targets multiple receptors involved in tumor angiogenesis and growth, including VEGFR, PDGFR, and c-Kit. It has shown potential in the treatment of various cancers, particularly advanced thyroid cancer. Motesanib works by inhibiting the signaling pathways involved in tumor cell proliferation and angiogenesis, offering a therapeutic approach for certain malignancies.

Reference

[1]. Polverino A, et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res, 2006, 66(17), 8715-8721.
[2]. Kruser TJ, et al. Augmentation of radiation response by motesanib, a multikinase inhibitor that targets vascular endothelial growth factor receptors. Clin Cancer Res, 2010, 16(14), 3639-3647.
[3]. Coxon A, et al. Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors. Clin Cancer Res, 2009, 15(1), 110-118.